Loading...
Please wait, while we are loading the content...
Similar Documents
PD-L1 and Emerging Biomarkers in Immune Checkpoint Blockade Therapy
| Content Provider | Scilit |
|---|---|
| Author | Cottrell, Tricia R. Taube, Janis M. |
| Copyright Year | 2018 |
| Description | Journal: The Cancer Journal PD-L1 checkpoint blockade is revolutionizing cancer therapy, and biomarkers capable of predicting which patients are most likely to respond are highly desired. The detection of PD-L1 protein expression by immunohistochemistry can enrich for response to anti–PD-(L)1 blockade in a variety of tumor types, but is not absolute. Limitations of current commercial PD-L1 immunohistochemical (IHC) assays and improvements anticipated in next-generation PD-L1 testing are reviewed. Assessment of tumor-infiltrating lymphocytes in conjunction with PD-L1 testing could improve specificity by distinguishing adaptive (interferon γ driven and cytotoxic T-lymphocyte associated) from constitutive (non–immune mediated) expression. The presence of a high tumor mutational burden also enriches for response to therapy, and early data indicate that this may provide additive predictive value beyond PD-L1 IHC alone. As candidate biomarkers continue to emerge, the pathologist's assessment of the tumor microenvironment on hematoxylin-eosin stain combined with PD-L1 IHC remains a rapid and robust way to evaluate the tumor-immune dynamic. |
| Related Links | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5830145/pdf |
| Ending Page | 46 |
| Page Count | 6 |
| Starting Page | 41 |
| ISSN | 15289117 |
| e-ISSN | 1540336X |
| DOI | 10.1097/ppo.0000000000000301 |
| Journal | The Cancer Journal |
| Issue Number | 1 |
| Volume Number | 24 |
| Language | English |
| Publisher | Ovid Technologies (Wolters Kluwer Health) |
| Publisher Date | 2018-01-01 |
| Access Restriction | Open |
| Subject Keyword | Journal: The Cancer Journal Pd-(l)1 Checkpoint Blockade |
| Content Type | Text |
| Resource Type | Article |
| Subject | Cancer Research Oncology |
